Bernhardt G. Zeiher Buys 10,000 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Bernhardt G. Zeiher bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average price of $3.70 per share, with a total value of $37,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $37,000. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Amylyx Pharmaceuticals Stock Performance

AMLX opened at $3.78 on Wednesday. The company has a fifty day moving average of $3.53 and a two-hundred day moving average of $4.02. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $7.27. The stock has a market capitalization of $334.92 million, a price-to-earnings ratio of -0.99 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter. On average, equities research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AMLX. Blue Trust Inc. grew its stake in Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after acquiring an additional 4,883 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $45,000. Alpine Global Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $45,000. RPO LLC acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth about $46,000. Finally, EntryPoint Capital LLC purchased a new position in Amylyx Pharmaceuticals in the 4th quarter valued at about $53,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.